Syros Pharmaceuticals (NASDAQ:SYRS) has been given a $28.00 target price by investment analysts at Oppenheimer in a research note issued on Wednesday. The firm presently has a “buy” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 211.46% from the stock’s current price.

Several other equities research analysts have also commented on SYRS. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. Roth Capital began coverage on Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $15.00 price objective for the company. Zacks Investment Research upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research note on Thursday, September 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Syros Pharmaceuticals has an average rating of “Buy” and an average target price of $26.14.

Syros Pharmaceuticals (SYRS) traded up $0.01 during midday trading on Wednesday, reaching $8.99. The company had a trading volume of 329,187 shares, compared to its average volume of 596,297. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.53). analysts forecast that Syros Pharmaceuticals will post -2.12 earnings per share for the current fiscal year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju acquired 109,774 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average cost of $9.03 per share, for a total transaction of $991,259.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average price of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of SYRS. Schwab Charles Investment Management Inc. purchased a new position in Syros Pharmaceuticals in the second quarter worth approximately $343,000. Rhumbline Advisers acquired a new position in Syros Pharmaceuticals during the second quarter worth $198,000. Bank of New York Mellon Corp lifted its stake in Syros Pharmaceuticals by 157.9% during the second quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after purchasing an additional 18,382 shares in the last quarter. Teachers Advisors LLC lifted its stake in Syros Pharmaceuticals by 360.5% during the second quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock worth $366,000 after purchasing an additional 17,785 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in Syros Pharmaceuticals by 646.3% during the second quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock worth $553,000 after purchasing an additional 29,782 shares in the last quarter. Institutional investors own 58.02% of the company’s stock.

WARNING: “Oppenheimer Analysts Give Syros Pharmaceuticals (SYRS) a $28.00 Price Target” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/17/oppenheimer-analysts-give-syros-pharmaceuticals-syrs-a-28-00-price-target.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.